Loading...
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort...
Na minha lista:
| Udgivet i: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7280047/ https://ncbi.nlm.nih.gov/pubmed/32286905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03279 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|